Phase II study of weekly irinotecan and cisplatin for refractory or recurrent non-small cell lung cancer
| Autor: | Katsushi Kurosu, Yuichi Takiguchi, Yuji Tada, Yoshiko Asaka-Amano, Tatsuo Kawashima, Keiichi Nagao, T Moriya, Takayuki Kuriyama |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine Oncology Cancer Research medicine.medical_specialty Lung Neoplasms Drug-Related Side Effects and Adverse Reactions medicine.medical_treatment Phases of clinical research Antineoplastic Agents Kaplan-Meier Estimate Neutropenia Irinotecan Drug Administration Schedule Refractory Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Survival rate Aged Cisplatin Chemotherapy business.industry Middle Aged medicine.disease Surgery Regimen Drug Resistance Neoplasm Camptothecin Female Neoplasm Recurrence Local business medicine.drug |
| Zdroj: | Lung Cancer. 58:253-259 |
| ISSN: | 0169-5002 |
| DOI: | 10.1016/j.lungcan.2007.06.004 |
| Popis: | Even with the standard first-line chemotherapy, advanced non-small cell lung cancer (NSCLC) recurs in most cases. The purpose of this study is to develop a new chemotherapeutic regimen for patients with NSCLC that has relapsed or was refractory to previous chemotherapy. Patients with proven NSCLC refractory or recurrent after previous single-regimen chemotherapy, PS of 0-2, age of 15 years or older, adequate organ functions and measurable lesions were treated with irinotecan at 60 mg/m(2) and cisplatin at 25 mg/m(2) with 1000 ml hydration on day 1. This administration, considered as one cycle, was repeated every week without rest unless encountering defined skip and dose-reduction criteria. The treatment was administered for six cycles over a 49-day period, both median values, to 48 patients, with a response rate of 26%, progression free and median survival times of 3 and 11 months, respectively, and a 1-year survival rate of 46%. The most frequent grade 3 or 4 toxicities were neutropenia, anaemia and nausea, which were manageable. Subset analyses suggested that the response rate was independent of response to the first-line chemotherapy. In conclusion, second-line chemotherapy of weekly irinotecan and cisplatin with minimum hydration seemed effective, with tolerable toxicity, and is potentially useful irrespective of the outcome of previous chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect